阿尔法tACS改善认知和调节神经传递在痴呆症的莱维体
Alberto Benussi1,2, Valentina Cantoni3, Jasmine Rivolta3
1Neurology Unit, Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy.
概括
跨交替电流刺激 (tACS) 在患有勒维体痴呆症 (DLB) 患者中改善了认知功能. 这种非侵入性脑刺激增强了视觉空间和执行功能,显示了DLB治疗的前景.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗器械 医疗器械
背景情况:
- 患有莱维体痴呆症 (DLB) 呈现出改变的脑电图 (EEG) 功率,从阿尔法频率转移到 Θ频率.
- 跨交替电流刺激 (tACS) 是一种非侵入性技术,用于在特定频率上引入大脑振荡.
研究的目的:
- 为了研究尾alpha (α) -tACS对DLB患者认知表现的影响.
- 评估与DLB中α-tACS相关的神经生理变化.
主要方法:
- 一个双盲,随机化,假控制,交叉试验,涉及14名DLB参与者.
- 参与者接受了60分钟,12赫兹,3mA峰值至峰值α-tACS或在皮层进行假刺激.
- 认知功能 (视觉空间,执行,口头情节性记忆) 和神经生理测量 (EEG) 被评估.
主要成果:
- 在DLB患者中,尾α-tACS是安全的,并且耐受良好.
- 在视觉空间能力和执行功能方面观察到显著的改善.
- 神经生理学变化包括α功率增加,Δ功率下降,以及增强的短延迟 afferent抑制.
结论:
- 尾部α-tACS是一种安全的治疗方法,可以增强DLB的关键认知功能.
- 观察到的神经生理学变化表明胆固醇通路和大脑振荡的参与.
- 需要进一步研究α-tACS作为DLB的治疗方法.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
112
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
112
Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108
Role of Neurotransmitters in Memory
494
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
494


